Fig 1.
Flow Diagram.
Fig 2.
Protocol of drug administration.
Table 1.
Main characteristics of the studied patients at time of inclusion.
Table 2.
Comparative efficacy between ALF-5755 and placebo on the PR slope from H0 to H72 and the survival without liver transplantation.
Table 3.
Values of PR slope from H0 to H72 according to the etiology of the acute liver failure.
Table 4.
ALF-5755 efficacy in HBV or AIH related severe acute hepatitis.
Fig 3.
Median time for patients to reach a PR rate > = 50% in the HBV-HAI patients receiving ALF-5755 (full line) or placebo (dotted line).
Analysis was performed on the ITT group (n = 22). Comparison by log-rank test was significant at the 0.03 level.
Table 5.
Treatment Emergent Adverse Events.